| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-665 | |
| Phytochemical name or plant extracts | Camptothecine | |
| PMID | 23474217 | |
| Literature evidence | These results are the first reports of camptothecine and its derivatives in these species and offer rich alternative plant sources for the anticancer compound, camptothecine. | |
| IUPAC name | (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione | |
| Phytochemicals’ class or type of plant extracts | Alkaloid | |
| Source of phytochemicals or plant Extracts | Miquelia dentata | |
| Geographical availability | India | |
| Plant parts | Seeds | |
| Other cancers | Breast cancer, Ovarian cancer, Liver cancer, Lung cancer, Squamous cancer, Colon cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 3.82 μg/ml against MDA-MB-273 4.0 µg/mL, 0.37 µM against MCF-7 2.36 µM, 250 nM against MDA-MB-231 | |
| Potency | Crude extract preparations of the seeds of M. dentata were effective against a breast cancer cell line (IC50=3.82 μg/ml for MDA MB273 cell lines) and two ovarian cancer cell lines (IC50=2.8 μg/ml for NCI/ADR-RES and 4.5 μg/ml for SKOV). | |
| Cell line/ mice model | MDA-MB-273, NCI/ADR-RES, SKOV, HepG2, Hep3B, MDA-MB- 231, MCF-7, A549, Ca9-22, NCI/ADR-RES, Hela, HCT116, GI 101A, MDA-MB-157 | |
| Additional information | These results are the first reports of camptothecine and its derivatives in these species and offer rich alternative plant sources for the anticancer compound, camptothecine. Causes accumulation of cells in G2/M phase at low doses in GI 101A cells, while at higher doses (50nM), causes accumulation of cells in the S phase (in MDA-MB-157, MDA-MB-231 and GI 101A cells) | |
| PubChem ID | 24360 | |
| Additional PMIDs | 9332461 33812607 18596662 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:608051-1 | |
| Safety | NA |